<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435928</url>
  </required_header>
  <id_info>
    <org_study_id>D1050238</org_study_id>
    <nct_id>NCT01435928</nct_id>
  </id_info>
  <brief_title>PEARL Schizophrenia Maintenance</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Of Lurasidone For The Maintenance Treatment Of Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This
      clinical study is designed to test the hypothesis that Lurasidone is effective in the long
      term maintenance treatment of schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Relapse Event During Double-blind Phase</measure>
    <time_frame>Double-blind phase - 28 Weeks</time_frame>
    <description>The Kaplan-Meier method is used for the estimation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to All-cause Discontinuation</measure>
    <time_frame>Double-blind phase - 28 weeks</time_frame>
    <description>The Kaplan-Meier method was used for estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Double-blind Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score</measure>
    <time_frame>Double-Blind phase - 28 Weeks</time_frame>
    <description>The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three scales: the Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Double-blind Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score</measure>
    <time_frame>Double-blind phase - 28 Weeks</time_frame>
    <description>The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>Double-blind phase - 28 Weeks</time_frame>
    <description>The MADRS consists of 10 items, each rated on a Likert scale, from 0=&quot;Normal&quot; to 6=&quot;Most Severe&quot;. The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Double-blind Baseline in Short Form-12v2 Health Survey (SF-12v2) Physical Component Score</measure>
    <time_frame>Double-blind phase - 28 Weeks</time_frame>
    <description>The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales.
Physical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Double-blind Baseline in Modified Specific Levels of Functioning (SLOF) Total Score</measure>
    <time_frame>Double-blind phase - 28 Weeks</time_frame>
    <description>The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items divided into two subscales: Social functioning (comprised of 7 items from interpersonal relationships section) and Community Living Skills (comprised of 17 items from activities and work skills sections). Each item is rated on a 5-point scale and mapped to 0 to 4 with a higher score indicating worse condition. The total score will be the sum of all 24 items and ranges from 0 to 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Adherence Rating Scale</measure>
    <time_frame>Double-blind phase - 28 Weeks</time_frame>
    <description>The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 - 100%) of doses taken by the subject in the previous month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking Questionnaire (Average Number of Cigarettes Per Day) at Week 28 (LOCF)</measure>
    <time_frame>28 Weeks - Double Blind Phase</time_frame>
    <description>Smoking history and frequency were assessed during the study by a research staff member. During the study, smoked subjects were asked about the average number of cigarettes per day they smoked over the last week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intent to Attend (ITA) Assessment at Open-label Baseline</measure>
    <time_frame>Open Label Baseline</time_frame>
    <description>The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = &quot;Not at all&quot; and 9 = &quot;Extremely&quot;. The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the screening visit: &quot;How likely is it that you will complete the study?&quot;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>EuroQol (EQ-5D): EQ-VAS Score</measure>
    <time_frame>Double-blind phase - 28 Weeks</time_frame>
    <description>The EQ-5D is a self-administered, standardized measure of health states consisting of two parts: EQ-5D descriptive system consisting of one question in each of five dimensions (mobility, self-care, pain, usual activities, and anxiety) with three possible response levels per question, classifying patients into one of 243 distinct health states, and a 20-cm visual analogue health status rating.
The 20-cm visual analog scale (VAS) has endpoints labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state&quot; that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">676</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Lurasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
    <arm_group_label>Lurasidone</arm_group_label>
    <other_name>Latuda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Open Label:

        Subject provides written informed consent and is willing and able to comply with the
        protocol in the opinion of the Investigator.

        Subject is ≥ 18 and ≤ 75 years of age, on the day of signing the informed consent.

        Subject meets DSM-IV-TR criteria for a primary diagnosis of schizophrenia [including
        disorganized (295.10), paranoid (295.30), undifferentiated (295.90) subtypes as established
        by clinical interview (using the DSM-IV-TR as a reference and confirmed using the
        SCID-CT)]. The duration of the subject's illness whether treated or untreated must be ≥ 1
        year.

        Subject has had at least one prior episode of psychotic exacerbation as judged by the
        Investigator in the two years preceding screening.

        Subject has a PANSS Total score ≥ 80 with a score ≥ 4 on 1 or more of any PANSS Positive
        subscale items at screening and open-label baseline (Visit 2).

        Subject has a CGI-S score of ≥ 4 at screening and open-label baseline (Visit 2).

        Subject is not pregnant (must have a negative serum pregnancy test at screening) or nursing
        (must not be lactating) and is not planning pregnancy within the projected duration of the
        study.

        Female subject of reproductive potential agrees to remain abstinent or use adequate and
        reliable contraception throughout the study and for at least 30 days after the last dose of
        lurasidone has been taken. In the Investigator's judgment, the subject will adhere to this
        requirement.

        Adequate contraception is defined as continuous use of either two barrier methods (e.g.,
        condom and spermicide or diaphragm with spermicide) or a hormonal contraceptive. Acceptable
        hormonal contraceptives include the following: a) contraceptive implant (such as Norplant®)
        implanted at least 90 days prior to screening; b) injectable contraception (such as
        medroxyprogesterone acetate injection) given at least 14 days prior to screening; or c)
        oral contraception taken as directed for at least 30 days prior to screening.

        Subjects who are of non-reproductive potential, i.e., subject who is surgically sterile,
        has undergone tubal ligation, or is postmenopausal (defined as at least 12 months of
        spontaneous amenorrhea or between 6 and 12 months of spontaneous amenorrhea with follicle
        stimulating hormone (FSH) concentrations within postmenopausal range as determined by
        laboratory analysis) are not required to remain abstinent or use adequate contraception.

        Subject is able and agrees to remain off prior antipsychotic medication for the duration of
        the study.

        Subject has had a stable living arrangement at the time of screening and agrees to return
        to a similar living arrangement after discharge, if hospitalized. This criterion is not
        meant to exclude subjects who have temporarily left a stable living arrangement (e.g., due
        to psychosis). Such subjects remain eligible to participate in this protocol. Chronically
        homeless subjects should not be enrolled.

        Subject is in good physical health on the basis of medical history, physical examination,
        and laboratory screening.

        Subject who requires concomitant medication treatment with the following agents may be
        included if they have been on stable doses (i.e., minor adjustments only) for the specified
        times: 1) antidepressant agents (except fluvoxamine) and/or mood stabilizers (except
        carbamazepine or oxcarbazepine) must be stable for at least 30 days prior to open-label
        baseline, 2) oral hypoglycemics must be stable for at least 30 days prior to screening, 3)
        antihypertensive agents must be stable for at least 30 days prior to screening, and 4)
        thyroid hormone replacement must be stable for at least 90 days prior to screening. (Note:
        CYP3A4 inducers and inhibitors will not be allowed).

        Subject is willing and able to comply with the protocol assessments and visits, in the
        opinion of the study nurse/coordinator and the Investigator.

        Double-blind -

        Subject must achieve and maintain clinical stability for a total of at least 12 weeks in
        the open label phase, defined as:

          1. a PANSS Total score ≤ 70, a CGI-S score &lt; 4 and a PANSS item score of ≤ 4 (moderate or
             less) on all PANSS Positive subscale items over at least 12 weeks with the allowance
             of two excursions (except during the last 4 weeks of the open-label phase) assessed at
             weekly study visits:

             • An excursion is defined as a PANSS total score up to a maximum of 80 and/or a CGI-S
             score up to a maximum of 4 and/or a PANSS Positive subscale item score up to a maximum
             of 5.

          2. a PANSS item score of ≤ 4 (moderate or less) on item G8 (uncooperativeness)

          3. taking a stable dose of lurasidone for the last 4 weeks of the open-label phase.

        Exclusion Criteria:

        Open Label - Subject has a DSM-IV Axis I or Axis II diagnosis other than schizophrenia that
        has been the primary focus of treatment within 3 months of screening.

        Subject answers &quot;yes&quot; to &quot;Suicidal Ideation&quot; item 4 (active suicidal ideation with some
        intent to act, without specific plan) or item 5 (active suicidal ideation with specific
        plan and intent) on the C-SSRS assessment at screening (in the past month) or baseline.

        Subject has attempted suicide within 3 months prior to the screening phase. Subject
        currently has a clinically significant medical condition including the following:
        neurological, metabolic (including Type 1 diabetes), hepatic, renal, hematological,
        pulmonary, cardiovascular, gastrointestinal, and/or urological disorder such as unstable
        angina, congestive heart failure (uncontrolled), or central nervous system (CNS) infection
        that would pose a risk to the subject if they were to participate in the study or that
        might confound the results of the study. Subjects with human immunodeficiency virus (HIV)
        seropositivity (or history of seropositivity) will be excluded.

        Note: Active medical conditions that are minor or well-controlled are not exclusionary if
        they do not affect risk to the subject or the study results. In cases in which the impact
        of the condition upon risk to the subject or study results is unclear, the Medical Monitor
        should be consulted. Any subject with a known cardiovascular disease or condition (even if
        controlled) must be discussed with the Medical Monitor before being screened.

        Subject has evidence of any chronic organic disease of the CNS such as tumors,
        inflammation, and active seizure disorder, vascular disorder, Parkinson's disease,
        Alzheimer's disease or other forms of dementia, myasthenia gravis, or other degenerative
        processes. In addition, subject must not have a history of mental retardation or persistent
        neurological symptoms attributable to serious head injury. Note: Past history of febrile
        seizures, drug-induced seizures, or alcohol withdrawal seizures is not exclusionary.

        Note: Past history of febrile seizures, drug-induced seizures, or alcohol withdrawal
        seizures is not exclusionary.

        Subject demonstrates evidence of acute hepatitis, clinically significant chronic hepatitis,
        or evidence of clinically significant impaired hepatic function through clinical and
        laboratory evaluation.

        Note: Subjects with serum alanine transaminase (ALT) or aspartate transaminase (AST) levels
        ≥ 3 times the upper limit of the reference ranges provided by the central laboratory
        require retesting. If on retesting, the laboratory value remains ≥ 3 times the upper limit,
        such subjects will be discussed with the Medical Monitor for enrollment consideration.

        Subject has a history of stomach or intestinal surgery or any other condition that could
        interfere with or is judged by the Investigator to interfere with absorption, distribution,
        metabolism, or excretion of study drug.

        Subject with Type 1 or Type 2 insulin-dependent diabetes.

        Subject with newly diagnosed Type 2 diabetes during screening. Subject with Type 2 diabetes
        is eligible for study inclusion if the following condition is met at screening:

        if a subject is currently being treated with oral anti-diabetic medication(s), the dose
        must have been stable for at least 4 weeks prior to screening. Such medication may be
        adjusted or discontinued during the study, as clinically indicated.

        Subject has any abnormal laboratory parameter at screening that indicates a clinically
        significant medical condition as determined by the Investigator. Subjects with a fasting
        blood glucose at screening ≥ 126 mg/dL (7.0 mmol/L) or HbA1c ≥ 7.0% will be excluded.

        Note: Subjects with random (non-fasting) blood glucose at screening ≥ 200 mg/dL (11.1
        mmol/L) must be retested in a fasted state.

        Subject has a prolactin concentration &gt; 100 ng/mL at screening or has a history of
        pituitary adenoma.

        Subject has a history of malignancy &lt; 5 years prior to signing the informed consent, except
        for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
        Pituitary tumors of any duration are excluded.

        Subject is judged to be resistant to antipsychotic treatment defined as any one of the
        following:

          1. failure to respond to &gt; 2 marketed antipsychotic agents, given at an adequate dose and
             for an adequate duration (within the past 2 years)

          2. history of treatment with clozapine for refractory psychosis Subject is unlikely to
             achieve a stable condition for ≥ 12 weeks during the open-label lurasidone phase based
             on the totality of evidence from the psychiatric history and/or the current
             presentation.

        Subject is receiving an antipsychotic medication above the maximum recommended
        (country-specific) dose at or prior to screening and, in the judgment of the Investigator,
        is unlikely to respond to standard doses of lurasidone.

        Subject has received depot antipsychotics unless the last injection was at least one
        treatment cycle or at least 30 days (whichever is longer) prior to the screening phase.

        Subject has received treatment with MAO inhibitors within 14 days prior to the screening
        phase.

        Subject requires treatment with any potent CYP3A4 inhibitors or inducers during the study
        (see Appendix 3).

        Subject has received electroconvulsive therapy treatment within the 3 months prior to
        screening or is expected to require electroconvulsive therapy (ECT) during the study.

        Subject has a history of neuroleptic malignant syndrome. Subject exhibits evidence of
        severe tardive dyskinesia, severe dystonia, or any other severe movement disorder. Severity
        will be determined by the Investigator.

        Subject has a history of alcohol or substance abuse (DSM-IV-TR criteria) within 3 months
        prior to screening or alcohol or substance dependence (DSM-IV-TR criteria) within 12 months
        prior to screening. The only exceptions include caffeine or nicotine abuse/dependence.

        Subject tests positive for drugs of abuse at screening. In the event a subject tests
        positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate the
        subject's ability to abstain from using this drug during the study. This information will
        be discussed with the Medical Monitor prior to study enrollment.

        Subject had a history or presence of an abnormal electrocardiogram (ECG), which in the
        Investigator's opinion is clinically significant (Medical Monitor may be consulted to
        determine clinical significance).

        Subject has poor peripheral venous access that will limit the ability to draw blood as
        judged by the Investigator.

        Subject has a history of hypersensitivity to more than 2 distinct chemical classes of drug
        (e.g., sulfas and penicillins).

        Subject was screened or washed out previously more than three times for this study.

        Subject is currently participating, or has participated in, a study with an investigational
        or marketed compound or device within 3 months prior to signing the informed consent, or
        has participated in 2 or more studies within 12 months prior to signing the informed
        consent.

        Subject is homeless or did not have a stable residence for the 3 months prior to the
        screening phase.

        Subject is unable to cooperate with any study procedures, unlikely to adhere to the study
        procedures and keep appointments, in the opinion of the Investigator, or was planning to
        relocate during the study.

        Subject requires guardianship under the laws of his/her country.

        Double-blind - Subjects who in the Investigator's judgment have not been compliant with
        study medication during the open-label stabilization phase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woodland Research Northwest</name>
      <address>
        <city>Springdale</city>
        <state>Arizona</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K&amp;S Professional Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Development Inc.</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diligent Clinical Trials</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research Center</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excell Clinical Trials</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNRI - Los Angeles LLC,8309 Telegraph Road</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuropsychopharmacology Clinical Research Instit</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Orange County</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network Inc.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Trials</name>
      <address>
        <city>Kissimme</city>
        <state>Florida</state>
        <zip>34742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive NeuroScience, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lousiana Clinical Research, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CBH Health LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Care and Research Center</name>
      <address>
        <city>O'Fallon</city>
        <state>Missouri</state>
        <zip>63368</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psych Care Consultants Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horne Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide LLC</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New York, Dept. of Psychiatry</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurobehavioral Research, Inc.</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>11516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Development, Inc</name>
      <address>
        <city>Fresh Meadows</city>
        <state>New York</state>
        <zip>11366</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Medical Research of Staten Island</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide LLC at Kirkbride</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Research</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Clinical Trials LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Clinical Trials, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Institute</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand - CMP B</name>
      <address>
        <city>Clermont-Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Specialise du Jura - Centre Medico Psychiatric</name>
      <address>
        <city>Dole</city>
        <zip>39100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Guillaume Regnier</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35703</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Chalucet, Centre hospitalier intercommunal de toulon la Seyne sur mer (CHITS)</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical</name>
      <address>
        <city>Toulouse</city>
        <zip>31200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC SPDC-Edificio n. 7, Ospedale S. Andrea</name>
      <address>
        <city>La Spezia</city>
        <zip>19123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Salute Mentale ASL 1</name>
      <address>
        <city>Massa</city>
        <zip>54100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Santa Chiara, U.O di Psichiatria 1 building n.4</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Government Institution Kipetsk Regional Psychoneurology Hospital</name>
      <address>
        <city>Lipetsk</city>
        <zip>399083</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company (LLC) Research Center for Treatment and rehabilitation &quot;Phoenix&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Psychoneurological Dispensary #7 (with Hospital)</name>
      <address>
        <city>St-Petersburg</city>
        <zip>190005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Healthcare Institution City Psychoneurology Dispensary #7 (with in-patient dept.) (SPb SBHI CPNDD-7), at daycare facility #1</name>
      <address>
        <city>St. Petersburg</city>
        <zip>19005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Healthcare Institution (SPbSH) &quot;City Psychiatric Hospital #6&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Government Healthcare Institution City Psychiatric Hospital #4 (St. Petersburg Insane Asylum Distributor)</name>
      <address>
        <city>St. Petersburg</city>
        <zip>19119</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Mental Health</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy, Clinic for Psychiatry</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Kragujevac, Clinic for Psychiatry</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Nis, Clinic for mental health protection</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for psychiatric diseases &quot;Sveti Vracevi&quot;</name>
      <address>
        <city>Novi Knezevac</city>
        <zip>23330`</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Vojvodina, Clinic for Psychiatry</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemonnica s poliklinikou v Prievidzi so sidlom v Bojniciach, Psychiatricke oddelenie</name>
      <address>
        <city>Bojnice</city>
        <zip>972 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulancia Mentum, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>82007</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka nemocnica Michalovce</name>
      <address>
        <city>Michalovce</city>
        <zip>071 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PsychoLine s.r.o. Psychiatricka ambulancia</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>97901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiaticke oddelenie Vseobecna nemocnica Riimavska Sobota, NaP n.o.</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>97912</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricke oddelenie, Nemocnica s poliklinikou sv. Barbory Roznava, a.s.</name>
      <address>
        <city>Roznava</city>
        <zip>048 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum zdravia R. B.K. s.r.o. Psychiatricka ambulancia</name>
      <address>
        <city>Svidnik</city>
        <zip>08901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Unit, Department of Psychiatry Free State Psychiatric Complex</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Trial Centre</name>
      <address>
        <city>Cape Town, W. Cape</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denmar Hospital Consulting Rooms</name>
      <address>
        <city>Pretoria</city>
        <zip>0081</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Former Serbia and Montenegro</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Poland</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <results_first_submitted>July 25, 2014</results_first_submitted>
  <results_first_submitted_qc>September 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2014</results_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Lurasidone</keyword>
  <keyword>Latuda</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>During the Open Label Phase subjects will receive Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
        </group>
        <group group_id="P2">
          <title>Lurasidone</title>
          <description>During double blind phase subjects received Lurasidone flexibly dosed 40 or 80 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>During double blind phase subjects received matching placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open Label Phase - up to 24 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="676"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not meet stabilization criteria</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Terminated at study completion</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double Blind Phase - 28 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="121"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Terminated at study completion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse criteria met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lurasidone</title>
          <description>During double blind phase subjects received Lurasidone flexibly dosed 40 or 80 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>During double blind phase subjects received matching placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="144"/>
            <count group_id="B2" value="141"/>
            <count group_id="B3" value="285"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="11.38"/>
                    <measurement group_id="B2" value="42.4" spread="12.25"/>
                    <measurement group_id="B3" value="42.7" spread="11.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Relapse Event During Double-blind Phase</title>
        <description>The Kaplan-Meier method is used for the estimation.</description>
        <time_frame>Double-blind phase - 28 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Relapse Event During Double-blind Phase</title>
          <description>The Kaplan-Meier method is used for the estimation.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="174">Median and upper limit of the confidence interval could not be estimated. The median is not estimable for lurasidone because fewer than half of the subjects (43) had first relapse.</measurement>
                    <measurement group_id="O2" value="192" lower_limit="113">Upper limit of the confidence interval could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Log Rank</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to All-cause Discontinuation</title>
        <description>The Kaplan-Meier method was used for estimation.</description>
        <time_frame>Double-blind phase - 28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>Time to All-cause Discontinuation</title>
          <description>The Kaplan-Meier method was used for estimation.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" lower_limit="106">Upper limit of the confidence interval could not be estimated.</measurement>
                    <measurement group_id="O2" value="115" lower_limit="82" upper_limit="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <method>Log Rank</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Double-blind Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score</title>
        <description>The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three scales: the Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.</description>
        <time_frame>Double-Blind phase - 28 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-blind Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score</title>
          <description>The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three scales: the Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="1.33"/>
                    <measurement group_id="O2" value="12.4" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>ANCOVA</method>
            <method_desc>LOCF</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Double-blind Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score</title>
        <description>The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= ‘Normal, not at all ill’ to 7= ‘Among the most extremely ill patients’. A higher score is associated with greater illness severity.</description>
        <time_frame>Double-blind phase - 28 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-blind Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score</title>
          <description>The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= ‘Normal, not at all ill’ to 7= ‘Among the most extremely ill patients’. A higher score is associated with greater illness severity.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.087"/>
                    <measurement group_id="O2" value="0.74" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
            <method_desc>LOCF</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
        <description>The MADRS consists of 10 items, each rated on a Likert scale, from 0=”Normal” to 6=”Most Severe”. The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.</description>
        <time_frame>Double-blind phase - 28 Weeks</time_frame>
        <population>There were four Lurasidone subjects and 2 placebo subjects that had no post-baseline MADRS assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The MADRS consists of 10 items, each rated on a Likert scale, from 0=”Normal” to 6=”Most Severe”. The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.</description>
          <population>There were four Lurasidone subjects and 2 placebo subjects that had no post-baseline MADRS assessment.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.63"/>
                    <measurement group_id="O2" value="3.6" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.218</p_value>
            <method>ANCOVA</method>
            <method_desc>LOCF</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Double-blind Baseline in Short Form-12v2 Health Survey (SF-12v2) Physical Component Score</title>
        <description>The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales.
Physical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
        <time_frame>Double-blind phase - 28 Weeks</time_frame>
        <population>There were 5 Lurasidone subjects and 3 placebo subjects that had no post-baseline SF-12 assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-blind Baseline in Short Form-12v2 Health Survey (SF-12v2) Physical Component Score</title>
          <description>The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales.
Physical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
          <population>There were 5 Lurasidone subjects and 3 placebo subjects that had no post-baseline SF-12 assessment.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.398" spread="0.5354"/>
                    <measurement group_id="O2" value="-1.341" spread="0.5373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>ANCOVA</method>
            <method_desc>LOCF</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Double-blind Baseline in Modified Specific Levels of Functioning (SLOF) Total Score</title>
        <description>The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items divided into two subscales: Social functioning (comprised of 7 items from interpersonal relationships section) and Community Living Skills (comprised of 17 items from activities and work skills sections). Each item is rated on a 5-point scale and mapped to 0 to 4 with a higher score indicating worse condition. The total score will be the sum of all 24 items and ranges from 0 to 96.</description>
        <time_frame>Double-blind phase - 28 Weeks</time_frame>
        <population>There were 19 Lurasidone subjects and 20 placebo subjects that had no post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-blind Baseline in Modified Specific Levels of Functioning (SLOF) Total Score</title>
          <description>The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items divided into two subscales: Social functioning (comprised of 7 items from interpersonal relationships section) and Community Living Skills (comprised of 17 items from activities and work skills sections). Each item is rated on a 5-point scale and mapped to 0 to 4 with a higher score indicating worse condition. The total score will be the sum of all 24 items and ranges from 0 to 96.</description>
          <population>There were 19 Lurasidone subjects and 20 placebo subjects that had no post-baseline assessment.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.88"/>
                    <measurement group_id="O2" value="3.2" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>ANCOVA</method>
            <method_desc>LOCF</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Adherence Rating Scale</title>
        <description>The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 - 100%) of doses taken by the subject in the previous month.</description>
        <time_frame>Double-blind phase - 28 Weeks</time_frame>
        <population>There were 6 Lurasidone subjects and 2 placebo subjects that had no post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Adherence Rating Scale</title>
          <description>The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 - 100%) of doses taken by the subject in the previous month.</description>
          <population>There were 6 Lurasidone subjects and 2 placebo subjects that had no post-baseline assessment.</population>
          <units>percentage of monthly doses taken</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" spread="4.42"/>
                    <measurement group_id="O2" value="98.9" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>EuroQol (EQ-5D): EQ-VAS Score</title>
        <description>The EQ-5D is a self-administered, standardized measure of health states consisting of two parts: EQ-5D descriptive system consisting of one question in each of five dimensions (mobility, self-care, pain, usual activities, and anxiety) with three possible response levels per question, classifying patients into one of 243 distinct health states, and a 20-cm visual analogue health status rating.
The 20-cm visual analog scale (VAS) has endpoints labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state&quot; that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day.</description>
        <time_frame>Double-blind phase - 28 Weeks</time_frame>
        <population>There were 5 Lurasidone subjects and 3 placebo subjects that had no post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQol (EQ-5D): EQ-VAS Score</title>
          <description>The EQ-5D is a self-administered, standardized measure of health states consisting of two parts: EQ-5D descriptive system consisting of one question in each of five dimensions (mobility, self-care, pain, usual activities, and anxiety) with three possible response levels per question, classifying patients into one of 243 distinct health states, and a 20-cm visual analogue health status rating.
The 20-cm visual analog scale (VAS) has endpoints labeled &quot;best imaginable health state&quot; and &quot;worst imaginable health state&quot; that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day.</description>
          <population>There were 5 Lurasidone subjects and 3 placebo subjects that had no post-baseline assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="19.87"/>
                    <measurement group_id="O2" value="68.2" spread="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smoking Questionnaire (Average Number of Cigarettes Per Day) at Week 28 (LOCF)</title>
        <description>Smoking history and frequency were assessed during the study by a research staff member. During the study, smoked subjects were asked about the average number of cigarettes per day they smoked over the last week.</description>
        <time_frame>28 Weeks - Double Blind Phase</time_frame>
        <population>ITT Subjects who smoked</population>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Questionnaire (Average Number of Cigarettes Per Day) at Week 28 (LOCF)</title>
          <description>Smoking history and frequency were assessed during the study by a research staff member. During the study, smoked subjects were asked about the average number of cigarettes per day they smoked over the last week.</description>
          <population>ITT Subjects who smoked</population>
          <units>number of cigarettes smoked daily</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="12.76"/>
                    <measurement group_id="O2" value="8.2" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intent to Attend (ITA) Assessment at Open-label Baseline</title>
        <description>The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = “Not at all” and 9 = “Extremely”. The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the screening visit: “How likely is it that you will complete the study?”</description>
        <time_frame>Open Label Baseline</time_frame>
        <population>All subjects who were randomized and received at least one dose of study medication in the double-blind phase. Subjects were analyzed based on the treatment they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone</title>
            <description>Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Lurasidone: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily in the evening with a meal or 30 minutes after eating
Matching Placebo: Matching placebo once daily in the evening with a meal or 30 minutes after eating</description>
          </group>
        </group_list>
        <measure>
          <title>Intent to Attend (ITA) Assessment at Open-label Baseline</title>
          <description>The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = “Not at all” and 9 = “Extremely”. The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the screening visit: “How likely is it that you will complete the study?”</description>
          <population>All subjects who were randomized and received at least one dose of study medication in the double-blind phase. Subjects were analyzed based on the treatment they were randomized.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="1.48"/>
                    <measurement group_id="O2" value="8.0" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the open label phase - all subjects SAEs and AEs were reported over 24 weeks. For the double blind phase, lurasidone and placebo, SAEs and AEs were reported over 28 weeks. The study was stopped once the anticipated number of relapses were reached.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>During the Open Label Phase subjects will receive Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating</description>
        </group>
        <group group_id="E2">
          <title>Lurasidone</title>
          <description>During double blind phase subjects received Lurasidone flexibly dosed 40 or 80 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>During double blind phase subjects received matching placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="676"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Artial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Therapeutic response delayed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="676"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hyponytremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pin in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="676"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="676"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Transient ischemic attach</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="676"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="676"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="676"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hostility</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Substance induced psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="676"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="373" subjects_at_risk="676"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="79" subjects_affected="69" subjects_at_risk="676"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="45" subjects_affected="36" subjects_at_risk="676"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="31" subjects_affected="21" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="676"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="676"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="676"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="676"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="676"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="116" subjects_affected="77" subjects_at_risk="676"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="104" subjects_affected="94" subjects_at_risk="676"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="676"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="676"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="676"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="676"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="82" subjects_affected="62" subjects_at_risk="676"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="43" subjects_affected="35" subjects_at_risk="676"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="676"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="676"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="144"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="676"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In addition to the &lt;60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication; provided, if a multicenter publication is not forthcoming within 24 months following completion of study at all sites, the PI shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, CNS</name_or_title>
      <organization>Sunovion</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

